Cancer Therapeutics CRC Pty Ltd (CTx), established in 2007, is Australias first translational drug-discovery and development company. It was formed to bridge the gap between leading cancer research and the discovery and development of the next generation of cancer drugs, precision small-molecule drugs. These small-molecule drugs are expected to make up half of the global market in cancer drugs within 10 years. Funded under the Australian Governments Cooperative Research Centres scheme, CTx has garnered approximately AU$ 148 million in cash and in-kind contributions from the federal government and its participating institutes to operate for 7 years. These funds are being used to expand and integrate previously separate drug-discovery and development centers into one large multidisciplinary organization with the requisite resources and capabilities to make a significant impact in the global cancer drug-discovery industry.